

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than \$1 billion to diabetes research, including more than \$122 million in FY2006. More than 80 percent of JDRF's expenditures directly support research and research-related education. In FY2006, the Foundation funded more than 500 centers, grants, and fellowships in 20 countries.

AREAS OF SCIENTIFIC INVESTIGATION

- Artificial Pancreas
- Beta Cell Development
- Beta Cell Function
- Beta Cell Regeneration
- Clinical Trials
- Environmental Triggers
- Gene Therapy
- Genetics
- Hypoglycemia
- Immunology
- Islet Transplantation
- Nephropathy
- Neuropathy
- Retinopathy
- Stem Cells
- Technological Interventions
- Tolerance
- Wound Healing

JDRF'S RESEARCH GOALS

JDRF plays a unique role in setting the global direction of diabetes research resources, to ensure that they are used as effectively as possible as a "cure enterprise" to bring about a world without diabetes and its complications. To that end, the organization has identified a set of cure therapeutic goal areas on which it will focus its research funding efforts. JDRF believes some combination of these areas of research focus currently holds the best potential to lead to breakthrough cures and treatments for type 1 diabetes and its complications. JDRF will continue to actively pursue research within the framework of the following goals while remaining flexible enough to quickly respond to new opportunities as they arise:

- Stopping the immune system response that causes type 1 diabetes and restoring autoimmunity in new-onset patients
- Perfecting islet replacement strategies without chronic immunosuppression, including the creation of a renewable islet cell source
- Creating novel therapeutics for predicting, preventing, and reversing complications
- Regenerating the body's own beta cells without transplantation
- Achieving metabolic control through mechanical intervention, including the development of a closed-loop artificial pancreas

FY 2006 JDRF RESEARCH FUNDING

Autoimmunity:	\$41 million
Complications:	\$26 million
Islet Replacement	
Transplantation:	\$21 million
Renewable Cell Source:	\$20 million
Regeneration:	\$8 million
Metabolic Control:	\$6 million